BR0315958A - Composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto - Google Patents
Composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do compostoInfo
- Publication number
- BR0315958A BR0315958A BR0315958-2A BR0315958A BR0315958A BR 0315958 A BR0315958 A BR 0315958A BR 0315958 A BR0315958 A BR 0315958A BR 0315958 A BR0315958 A BR 0315958A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutically acceptable
- compounds
- general formula
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO, NOVOS INTERMEDIáRIOS E USO DO COMPOSTO". A presente invenção refere-se os compostos de 3aminoalcóxindolos substituídos da fórmula geral (I), seus estereoisómeros, seus rádio isótopos, suas formas geométricas, seus N-óxidos, seus polimorfos, seus sais farmaceuticamente aceitáveis, seus solvatos farmaceuticamente aceitáveis, seus metabólitos bio-ativos úteis e qualquer combinação dos acima mencionados. A invenção também revela os processos para a preparação de tais compostos da fórmula geral (I), os seus estereoisómeros, os seus rádio isótopos, as suas formas geométricas, os seus óxidos de N, os seus polimorfos, os seus sais farmaceuticamente aceitáveis, os seus solvatos farmaceuticamente aceitáveis, os seus metabólitos bio ativos úteis e também inclui qualquer combinação dos acima mencionados. Também são descritos em adição os vários métodos para a ministração destes compostos da fórmula geral (I), por exemplo as formas de dosagem farmaceuticamente aceitáveis, as suas composições e os seus usos tanto em uma terapia ou em um diagnóstico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN883MA2002 | 2002-11-28 | ||
| IN883/MAS/2002 | 2002-11-28 | ||
| PCT/IN2003/000370 WO2004048328A2 (en) | 2002-11-28 | 2003-11-25 | N-arylsulfonyl-3-aminoalkoxyindoles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0315958A true BR0315958A (pt) | 2005-09-13 |
| BRPI0315958B1 BRPI0315958B1 (pt) | 2018-06-26 |
| BRPI0315958B8 BRPI0315958B8 (pt) | 2021-05-25 |
Family
ID=34362365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0315958A BRPI0315958B8 (pt) | 2002-11-28 | 2003-11-25 | composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7507835B2 (pt) |
| EP (1) | EP1567492B1 (pt) |
| JP (2) | JP4782425B2 (pt) |
| KR (1) | KR100776118B1 (pt) |
| CN (2) | CN102249981A (pt) |
| AU (1) | AU2003285759B2 (pt) |
| BR (1) | BRPI0315958B8 (pt) |
| CA (1) | CA2507505C (pt) |
| CY (1) | CY1114241T1 (pt) |
| EA (1) | EA009193B1 (pt) |
| ES (1) | ES2425143T3 (pt) |
| MX (1) | MXPA05005700A (pt) |
| NO (1) | NO331805B1 (pt) |
| NZ (1) | NZ540842A (pt) |
| PT (1) | PT1567492E (pt) |
| SI (1) | SI1567492T1 (pt) |
| WO (1) | WO2004048328A2 (pt) |
| ZA (1) | ZA200504044B (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2425143T3 (es) * | 2002-11-28 | 2013-10-11 | Suven Life Sciences Limited | N-Arilsulfonil-3-aminoalcoxiindoles |
| EA009367B1 (ru) * | 2002-12-18 | 2007-12-28 | Сувен Лайф Сайенсиз Лимитед | ПРОИЗВОДНЫЕ 5-ТИА-5-ДИОКСО-4b-АЗАИНДЕНО[2,1-a]ИНДЕНА, ОБЛАДАЮЩИЕ АФФИННОСТЬЮ К РЕЦЕПТОРУ СЕРОТОНИНА |
| AU2004312229B2 (en) | 2004-01-02 | 2010-05-20 | Suven Life Sciences Limited | Novel Indeno[2,1a]indenes and isoindolo[2,1-a]indoles |
| PL1919896T3 (pl) | 2005-08-12 | 2010-05-31 | Suven Life Sciences Ltd | Pochodne aminoarylosulfonamidu jako funkcjonalne ligandy 5-HT6 |
| WO2007020654A1 (en) | 2005-08-16 | 2007-02-22 | Suven Life Sciences | An improved process for the preparation of losartan |
| KR100724095B1 (ko) * | 2005-10-21 | 2007-06-04 | 한국표준과학연구원 | 정밀 전류, 전압 및 전력 측정장치 |
| ES2357584T3 (es) | 2007-01-08 | 2011-04-27 | Suven Life Sciences Limited | Compuestos de 5-(heterociclil) alquil-n-(arilsulfonil)indol y su uso como ligandos de 5-th6. |
| EP1947085A1 (en) * | 2007-01-19 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Substituted indole sulfonamide compounds, their preparation and use as medicaments |
| WO2008136017A1 (en) | 2007-05-03 | 2008-11-13 | Suven Life Sciences Limited | Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands |
| MX2010003765A (es) | 2007-10-26 | 2010-04-30 | Suven Life Sciences Ltd | Compuestos de aminoarilsulfonamida y su uso como ligandos de la 5-hidroxitriptamina6. |
| AR072297A1 (es) * | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
| EP2149573A1 (en) * | 2008-08-01 | 2010-02-03 | Laboratorios Del. Dr. Esteve, S.A. | Substituted indole sulfonamide compounds their preparation and use as medicaments |
| WO2010032257A1 (en) | 2008-09-17 | 2010-03-25 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands |
| JP5536781B2 (ja) | 2008-09-17 | 2014-07-02 | スヴェン・ライフ・サイエンシズ・リミテッド | アリールスルホンアミドアミン化合物および５−ｈｔ６リガンドとしてのそれらの使用 |
| US9018231B2 (en) | 2010-01-05 | 2015-04-28 | Suven Life Sciences Limited | Sulfone compounds as 5-HT6 receptor ligands |
| EP2932922B1 (en) * | 2012-12-13 | 2018-09-05 | Olympus Corporation | Treatment device |
| DE102013013602A1 (de) * | 2013-08-19 | 2015-02-19 | Trützschler GmbH + Co KG Textilmaschinenfabrik | Vorrichtung an einer Karde oder Krempel für Baumwolle, Chemiefasern u. dgl. mit einer drehbaren Abstreifwalze |
| US9663498B2 (en) | 2013-12-20 | 2017-05-30 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE111890C (pt) | ||||
| US723550A (en) * | 1902-09-15 | 1903-03-24 | Eagle Lock Co | Padlock. |
| CH481104A (de) * | 1967-01-25 | 1969-11-15 | Geigy Ag J R | Verfahren zur Herstellung von neuen Indolderivaten |
| US3860608A (en) * | 1969-05-27 | 1975-01-14 | Novo Terapeutisk Labor As | 3-aminoalkyloxyindoles |
| GB1306230A (pt) * | 1969-05-27 | 1973-02-07 | ||
| US3860609A (en) * | 1969-05-27 | 1975-01-14 | Novo Terapeutisk Labor As | 3-aminoalkyloxyindoles |
| ZA795239B (en) | 1978-10-12 | 1980-11-26 | Glaxo Group Ltd | Heterocyclic compounds |
| ZA815541B (en) * | 1980-08-12 | 1983-03-30 | Glaxo Group Ltd | Heterocyclic compounds |
| JPS57200362A (en) | 1981-06-05 | 1982-12-08 | Mitsui Toatsu Chem Inc | Preparation of indoxyl |
| GB8600397D0 (en) | 1986-01-08 | 1986-02-12 | Glaxo Group Ltd | Chemical compounds |
| GB8719167D0 (en) | 1987-08-13 | 1987-09-23 | Glaxo Group Ltd | Chemical compounds |
| JPH01139564A (ja) * | 1987-08-31 | 1989-06-01 | Terumo Corp | Ｎ−置換インドールエステル化合物、その製造法ならびに該化合物を用いた試験組成物および試験具 |
| GB8724912D0 (en) | 1987-10-23 | 1987-11-25 | Wellcome Found | Indole derivatives |
| GB8819024D0 (en) | 1988-08-10 | 1988-09-14 | Glaxo Group Ltd | Chemical compounds |
| IL96891A0 (en) | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
| CA2042295A1 (fr) | 1990-05-15 | 1991-11-16 | Jacques Chauveau | Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant |
| AU646871B2 (en) | 1990-06-07 | 1994-03-10 | Astrazeneca Uk Limited | Therapeutic heterocyclic compounds |
| SK278998B6 (sk) | 1991-02-01 | 1998-05-06 | Merck Sharp & Dohme Limited | Deriváty imidazolu, triazolu a tetrazolu, spôsob i |
| GB9113802D0 (en) | 1991-06-26 | 1991-08-14 | Smithkline Beecham Plc | Medicaments |
| GB9210400D0 (en) | 1992-05-15 | 1992-07-01 | Merck Sharp & Dohme | Therapeutic agents |
| KR940007001A (ko) | 1992-09-16 | 1994-04-26 | 최승주 | 새로운 n-신나모일-2-메틸-5-메톡시-3-인돌 아세트산 에스테르, 그 제조방법 및 이를 함유하는 약학적 제제 |
| IL130169A (en) | 1999-05-27 | 2006-08-20 | Neurim Pharma 1991 | Indole derivatives, and pharmaceutical preparations, skin protection preparations, and cosmetics containing them |
| FR2799757B1 (fr) | 1999-10-15 | 2001-12-14 | Adir | Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2821843B1 (fr) * | 2001-03-12 | 2003-05-09 | Servier Lab | Nouveaux derives d'isoindoloindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1523486B1 (en) * | 2002-06-21 | 2007-11-07 | Suven Life Sciences Limited | Tetracyclic arylsulfonyl indoles having serotonin receptor affinity |
| RS51052B (sr) * | 2002-07-22 | 2010-10-31 | Basf Aktiengesellschaft | Herbicidne smeše koje deluju sinergetski |
| ES2425143T3 (es) * | 2002-11-28 | 2013-10-11 | Suven Life Sciences Limited | N-Arilsulfonil-3-aminoalcoxiindoles |
-
2003
- 2003-11-25 ES ES03778739T patent/ES2425143T3/es not_active Expired - Lifetime
- 2003-11-25 WO PCT/IN2003/000370 patent/WO2004048328A2/en active Application Filing
- 2003-11-25 BR BRPI0315958A patent/BRPI0315958B8/pt not_active IP Right Cessation
- 2003-11-25 EP EP03778739.7A patent/EP1567492B1/en not_active Expired - Lifetime
- 2003-11-25 KR KR1020057009253A patent/KR100776118B1/ko active IP Right Grant
- 2003-11-25 US US10/536,592 patent/US7507835B2/en not_active Expired - Fee Related
- 2003-11-25 JP JP2004554902A patent/JP4782425B2/ja not_active Expired - Fee Related
- 2003-11-25 NZ NZ540842A patent/NZ540842A/en not_active IP Right Cessation
- 2003-11-25 CN CN2011101270926A patent/CN102249981A/zh active Pending
- 2003-11-25 SI SI200332271T patent/SI1567492T1/sl unknown
- 2003-11-25 MX MXPA05005700A patent/MXPA05005700A/es active IP Right Grant
- 2003-11-25 CN CNA2003801046430A patent/CN1720227A/zh active Pending
- 2003-11-25 PT PT37787397T patent/PT1567492E/pt unknown
- 2003-11-25 EA EA200500882A patent/EA009193B1/ru not_active IP Right Cessation
- 2003-11-25 AU AU2003285759A patent/AU2003285759B2/en not_active Ceased
- 2003-11-25 CA CA2507505A patent/CA2507505C/en not_active Expired - Fee Related
-
2005
- 2005-06-10 NO NO20052825A patent/NO331805B1/no not_active IP Right Cessation
-
2006
- 2006-05-19 ZA ZA200504044A patent/ZA200504044B/en unknown
-
2009
- 2009-01-06 US US12/349,043 patent/US7718690B2/en not_active Expired - Fee Related
-
2011
- 2011-02-28 JP JP2011043072A patent/JP2011116769A/ja active Pending
-
2013
- 2013-08-14 CY CY20131100698T patent/CY1114241T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA009193B1 (ru) | 2007-12-28 |
| EP1567492A2 (en) | 2005-08-31 |
| NO20052825L (no) | 2005-08-25 |
| ZA200504044B (en) | 2006-07-26 |
| AU2003285759A1 (en) | 2004-06-18 |
| US20060173193A1 (en) | 2006-08-03 |
| CA2507505C (en) | 2011-10-04 |
| NZ540842A (en) | 2008-05-30 |
| EA200500882A1 (ru) | 2005-12-29 |
| JP4782425B2 (ja) | 2011-09-28 |
| ES2425143T3 (es) | 2013-10-11 |
| NO20052825D0 (no) | 2005-06-10 |
| JP2006511506A (ja) | 2006-04-06 |
| SI1567492T1 (sl) | 2013-07-31 |
| PT1567492E (pt) | 2013-07-22 |
| BRPI0315958B1 (pt) | 2018-06-26 |
| BRPI0315958B8 (pt) | 2021-05-25 |
| US7718690B2 (en) | 2010-05-18 |
| WO2004048328A3 (en) | 2004-10-28 |
| NO331805B1 (no) | 2012-04-10 |
| US20090131507A1 (en) | 2009-05-21 |
| CY1114241T1 (el) | 2016-08-31 |
| EP1567492B1 (en) | 2013-05-22 |
| CA2507505A1 (en) | 2004-06-10 |
| CN1720227A (zh) | 2006-01-11 |
| WO2004048328A2 (en) | 2004-06-10 |
| KR20050083963A (ko) | 2005-08-26 |
| CN102249981A (zh) | 2011-11-23 |
| KR100776118B1 (ko) | 2007-11-15 |
| JP2011116769A (ja) | 2011-06-16 |
| AU2003285759B2 (en) | 2010-01-28 |
| US7507835B2 (en) | 2009-03-24 |
| MXPA05005700A (es) | 2005-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0315958A (pt) | Composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto | |
| BRPI0410477A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto | |
| BR9907270A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto | |
| BR0214988A (pt) | S-enanciÈmero de um composto, composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento ou prevenção de diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica | |
| BRPI0215312B8 (pt) | composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto | |
| BRPI0414330A (pt) | composto, processo para preparação do mesmo, métodos para produção de um efeito antibacteriano, para inibição de dna girase bacteriana, e para tratamento de uma infecção bacteriana em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
| BR0211289A (pt) | Derivados de dolastatina 10 | |
| BR0208907A (pt) | Composto uso de um composto, composição farmacêutica, métodos para a terapia da dor em um animal de sangue quente e para a redução seletiva de uma porção nitro orto para um substituinte amino em um anel fenila ou piridila de um composto. | |
| BRPI0415613A (pt) | novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8 | |
| BR0313160A (pt) | Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto | |
| BR9812048A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos de tratar uma doença mediada por uma cinase, de tratar a rejeição no transplante de órgão, e de tratar a alopecia induzida pela quimioterapia | |
| BR0308816A (pt) | Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas | |
| BRPI0517619A (pt) | entidades quìmicas de imidazo[1,2-a] pirazin-8-ilaminas, suas composições farmacêuticas, uso dos referidos compostos na preparação de medicamento, processo de preparação de medicamento e métodos de utilização dos referidos compostos | |
| BR9806870A (pt) | Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, e, uso de um composto e processo para preparar o mesmo. | |
| BRPI0412527A (pt) | composto, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica, e, processo para preparar um composto. | |
| BR0209271A (pt) | Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto | |
| BRPI0113042B8 (pt) | composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato | |
| DE69529670D1 (de) | Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen | |
| BR0213242A (pt) | Composto ou um seu sal ou solvato, composto e seus sais de adição de ácido fisiologicamente aceitáveis, composição farmacêutica, método de tratamento de um ou mais distúrbios, uso de um composto, e, processo de preparação de um composto | |
| BR0210350A (pt) | Nucleosìdeos 4'-substituìdos | |
| BR0309875A (pt) | métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto | |
| BR9407910A (pt) | Composto composiçao farmacêutica uso do composto processo de tratamento de distúrbios no sistema nervoso central e processo de preparaçao do composto | |
| BR0209518A (pt) | Novos derivados arilheteroalquilamina | |
| BR0214243A (pt) | Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida | |
| BR9907934A (pt) | Composto, composição farmacêutica, e, processo para a preparação do composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] |
Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI |
|
| B07B | Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette] |
Free format text: ANULADA A PUBLICACAO DA RPI 2358 DE 15/03/2016, CONFORME SOLICITACAO FEITA PELA ANVISA ATRAVES DO OFICIO NO 110/2016-COOPI/GGMED/ANVISA, DE 10/05/2016, VISANDO REGULARIZAR O PEDIDO JUNTO A AGENCIA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/11/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2646 DE 21-09-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |